MetaVia (MTVA) Competitors $0.74 -0.01 (-1.33%) As of 02:27 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock MTVA vs. HOWL, TELO, CNTX, VNRX, DTIL, QNCX, ICCC, MGX, ADVM, and ANVSShould you be buying MetaVia stock or one of its competitors? The main competitors of MetaVia include Werewolf Therapeutics (HOWL), Telomir Pharmaceuticals (TELO), Context Therapeutics (CNTX), VolitionRx (VNRX), Precision BioSciences (DTIL), Quince Therapeutics (QNCX), ImmuCell (ICCC), Metagenomi (MGX), Adverum Biotechnologies (ADVM), and Annovis Bio (ANVS). These companies are all part of the "pharmaceutical products" industry. MetaVia vs. Its Competitors Werewolf Therapeutics Telomir Pharmaceuticals Context Therapeutics VolitionRx Precision BioSciences Quince Therapeutics ImmuCell Metagenomi Adverum Biotechnologies Annovis Bio Werewolf Therapeutics (NASDAQ:HOWL) and MetaVia (NASDAQ:MTVA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings. Which has preferable earnings & valuation, HOWL or MTVA? MetaVia has lower revenue, but higher earnings than Werewolf Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWerewolf Therapeutics$1.14M48.49-$37.37M-$1.67-0.74MetaViaN/AN/A-$12.47MN/AN/A Do analysts recommend HOWL or MTVA? Werewolf Therapeutics presently has a consensus target price of $8.33, suggesting a potential upside of 574.76%. MetaVia has a consensus target price of $7.50, suggesting a potential upside of 913.51%. Given MetaVia's higher possible upside, analysts clearly believe MetaVia is more favorable than Werewolf Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Werewolf Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00MetaVia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, HOWL or MTVA? Werewolf Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, MetaVia has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Is HOWL or MTVA more profitable? MetaVia has a net margin of 0.00% compared to Werewolf Therapeutics' net margin of -578.80%. Werewolf Therapeutics' return on equity of -58.83% beat MetaVia's return on equity.Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics-578.80% -58.83% -38.45% MetaVia N/A -189.12%-122.31% Do insiders and institutionals have more ownership in HOWL or MTVA? 64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 1.4% of MetaVia shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by company insiders. Comparatively, 1.1% of MetaVia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor HOWL or MTVA? In the previous week, MetaVia had 1 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 3 mentions for MetaVia and 2 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 1.21 beat MetaVia's score of 1.00 indicating that Werewolf Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Werewolf Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MetaVia 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in HOWL or MTVA? Werewolf Therapeutics received 31 more outperform votes than MetaVia when rated by MarketBeat users. However, 100.00% of users gave MetaVia an outperform vote while only 68.63% of users gave Werewolf Therapeutics an outperform vote. CompanyUnderperformOutperformWerewolf TherapeuticsOutperform Votes3568.63% Underperform Votes1631.37% MetaViaOutperform Votes4100.00% Underperform VotesNo Votes SummaryWerewolf Therapeutics beats MetaVia on 9 of the 14 factors compared between the two stocks. Get MetaVia News Delivered to You Automatically Sign up to receive the latest news and ratings for MTVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTVA vs. The Competition Export to ExcelMetricMetaViaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.48M$6.88B$5.59B$8.51BDividend YieldN/A2.53%5.28%4.17%P/E RatioN/A8.5427.2019.68Price / SalesN/A262.76409.08153.66Price / CashN/A65.8538.3234.64Price / Book0.226.526.974.61Net Income-$12.47M$143.48M$3.23B$248.06M7 Day Performance6.91%0.36%-0.72%-0.82%1 Month Performance13.85%11.11%8.00%3.74%1 Year PerformanceN/A2.62%31.77%13.02% MetaVia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTVAMetaVia2.4619 of 5 stars$0.74-1.3%$7.50+913.5%N/A$14.48MN/A0.008Positive NewsHOWLWerewolf Therapeutics3.8893 of 5 stars$1.34+0.8%$8.33+521.9%-58.0%$60.13M$1.14M-0.8840Positive NewsGap UpTELOTelomir Pharmaceuticals2.0386 of 5 stars$2.01-2.2%$15.00+648.1%-63.7%$59.68MN/A-3.461Gap UpCNTXContext Therapeutics3.0914 of 5 stars$0.66-1.7%$6.00+813.2%-67.4%$58.85MN/A-0.727Gap UpVNRXVolitionRx1.9832 of 5 stars$0.57+0.9%$3.50+518.4%-13.9%$58.31M$1.31M-1.5780Analyst UpgradeDTILPrecision BioSciences4.1743 of 5 stars$5.24+0.7%$47.00+797.8%-57.2%$58.05M$51.14M87.26200News CoverageQNCXQuince Therapeutics3.6591 of 5 stars$1.26+4.6%$8.00+537.5%+67.8%$57.06MN/A-1.0160News CoverageAnalyst ForecastICCCImmuCell0.6165 of 5 stars$6.29+0.5%N/A+49.7%$56.84M$27.30M-12.5870Short Interest ↓MGXMetagenomi2.1131 of 5 stars$1.51-4.1%$13.00+763.8%-76.0%$56.26M$45.26M-0.71236Gap DownADVMAdverum Biotechnologies3.9706 of 5 stars$2.70-3.3%$26.40+878.1%-67.1%$56.22M$1M-0.45190Short Interest ↑Gap DownANVSAnnovis Bio2.0834 of 5 stars$2.91+1.2%$30.25+938.1%-51.5%$56.22MN/A-0.653Analyst Revision Related Companies and Tools Related Companies HOWL Alternatives TELO Alternatives CNTX Alternatives VNRX Alternatives DTIL Alternatives QNCX Alternatives ICCC Alternatives MGX Alternatives ADVM Alternatives ANVS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTVA) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MetaVia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MetaVia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MTVA Stock Free MTVA Stock Alerts